Stock Scorecard
Stock Summary for NewAmsterdam Pharma Company NV (NAMS) - $29.79 as of 3/16/2026 8:35:08 PM EST
Total Score
9 out of 30
Safety Score
20 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for NAMS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for NAMS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for NAMS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for NAMS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for NAMS (20 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 1 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for NAMS
Financial Details for NAMS
Company Overview |
|
|---|---|
| Ticker | NAMS |
| Company Name | NewAmsterdam Pharma Company NV |
| Country | N/A |
| Description | NewAmsterdam Pharma Company N.V. is a pioneering biotechnology firm dedicated to developing innovative therapies for cardiometabolic diseases, leveraging its proprietary technology platform to tackle substantial unmet medical needs. With a strong focus on advanced drug discovery and a robust clinical development pipeline, the company aims to transform treatment paradigms and improve patient outcomes. Comprising a team of seasoned industry professionals, NewAmsterdam is well-positioned to emerge as a significant player in the biopharmaceutical sector, offering investors a promising outlook for growth through its novel therapeutic initiatives. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 12/31/2025 |
| Next Earnings Date | 5/7/2026 |
Stock Price History |
|
| Last Day Price | 29.79 |
| Price 4 Years Ago | 0.00 |
| Last Day Price Updated | 3/16/2026 8:35:08 PM EST |
| Last Day Volume | 1,078,726 |
| Average Daily Volume | 836,891 |
| 52-Week High | 42.00 |
| 52-Week Low | 14.06 |
| Last Price to 52 Week Low | 111.88% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 24.56 |
| Sector PE | 40.66 |
| 5-Year Average PE | -12.28 |
| Free Cash Flow Ratio | 6.99 |
| Industry Free Cash Flow Ratio | 10.30 |
| Sector Free Cash Flow Ratio | 22.88 |
| Current Ratio Most Recent Quarter | 7.88 |
| Total Cash Per Share | 4.26 |
| Book Value Per Share Most Recent Quarter | 5.97 |
| Price to Book Ratio | 5.02 |
| Industry Price to Book Ratio | 54.44 |
| Sector Price to Book Ratio | 36.53 |
| Price to Sales Ratio Twelve Trailing Months | 152.56 |
| Industry Price to Sales Ratio Twelve Trailing Months | 32.06 |
| Sector Price to Sales Ratio Twelve Trailing Months | 12.34 |
| Analyst Buy Ratings | 10 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 114,975,000 |
| Market Capitalization | 3,425,105,250 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 15.64% |
| Reported EPS 12 Trailing Months | -1.72 |
| Reported EPS Past Year | -1.59 |
| Reported EPS Prior Year | -2.46 |
| Net Income Twelve Trailing Months | -203,819,000 |
| Net Income Past Year | -203,819,000 |
| Net Income Prior Year | -241,598,000 |
| Quarterly Revenue Growth YOY | -99.80% |
| 5-Year Revenue Growth | -79.34% |
| Operating Margin Twelve Trailing Months | -206,188.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 490,002,000 |
| Total Cash Past Year | 490,002,000 |
| Total Cash Prior Year | 771,743,000 |
| Net Cash Position Most Recent Quarter | 490,002,000 |
| Net Cash Position Past Year | 490,002,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 683,431,000 |
| Total Stockholder Equity Prior Year | 757,500,000 |
| Total Stockholder Equity Most Recent Quarter | 683,431,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -148,029,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.29 |
| Free Cash Flow Past Year | -148,029,000 |
| Free Cash Flow Prior Year | -159,236,000 |
Options |
|
| Put/Call Ratio | 0.57 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.07 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 3/14/2026 4:01:19 AM EST |